Naldemedine
- TRADE NAME: Symproic (Shionogi)
- INDICATIONS: Opioid-induced constipation in adult patients with chronic non-cancer pain
- CLASS: Opioid antagonist, Opioid receptor antagonist
- HALF-LIFE: 11 hours
FDA APPROVAL DATE: 03/23/2017
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Amiodarone, Aprepitant, Atazanavir, Captopril, Carbamazepine, Clarithromycin, Cyclosporine, Diltiazem, Erythromycin, Fluconazole, Itraconazole, Ketoconazole, Moderate or strong CYP3A inhibitors, Other opioid antagonists, P-gp inhibitors, Phenytoin, Quercetin, Quinidine, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong CYP3A inducers, Verapamil
PREGNANCY CATEGORY: N/A
Potential for opioid withdrawal in fetus
Contra-indicated in patients with known or suspected gastrointestinal obstruction.
Opioid withdrawal symptoms have occurred in patients treated with naldemedine.
Please login to see the rest of this drug profile
SKIN.
GASTROINTESTINAL/HEPATIC.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
